Volume 11, Issue 2 (2026)
SJMR 2026, 11(2): 79-86 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Shafti V, Azarboo A. Risk of thrombosis in women undergoing in vitro fertilization: a narrative review.. SJMR 2026; 11 (2) : 5
URL: http://saremjrm.com/article-1-398-en.html
URL: http://saremjrm.com/article-1-398-en.html
1- Sarem Gynecology, Obstetrics and Infertility Research Center, Sarem Women’s Hospital, Iran University of Medical Science (IUMS), Tehran, Iran. & School of Medicine, Tonekabon Branch, Islamic Azad University, Tonekabon, Iran.
2- School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
2- School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
Abstract: (9 Views)
Summary:
Infertility is defined as the inability to conceive after more than 12 months of regular, unprotected sexual intercourse.
Thromboembolism is defined as a condition in which a thrombosis in a vein or artery, usually forming in the deep veins of the legs or pelvis, can travel to the pulmonary arteries,
resulting in a pulmonary embolism.
The association between medically assisted reproductive techniques and thromboembolic complications has been widely reported in numerous published studies. Although venous thromboembolism is not thought to be a common complication, it is associated with a high morbidity and is often preventable. As we continue to see an increase in the total number of cycles of medical treatments for reproduction, particularly in women over 40 years of age, coupled with a continued increase in the number of cycles of fertility preservation for both medical and social reasons, we are likely to see an increase in the absolute number of thromboembolic complications.
The aim of this review is to provide information on thromboembolic risk factors, thrombosis risk scoring, and best practice recommendations on risk reduction strategies for at-risk individuals undergoing ovarian stimulation and embryo transfer cycles.
Infertility is defined as the inability to conceive after more than 12 months of regular, unprotected sexual intercourse.
Thromboembolism is defined as a condition in which a thrombosis in a vein or artery, usually forming in the deep veins of the legs or pelvis, can travel to the pulmonary arteries,
resulting in a pulmonary embolism.
The association between medically assisted reproductive techniques and thromboembolic complications has been widely reported in numerous published studies. Although venous thromboembolism is not thought to be a common complication, it is associated with a high morbidity and is often preventable. As we continue to see an increase in the total number of cycles of medical treatments for reproduction, particularly in women over 40 years of age, coupled with a continued increase in the number of cycles of fertility preservation for both medical and social reasons, we are likely to see an increase in the absolute number of thromboembolic complications.
The aim of this review is to provide information on thromboembolic risk factors, thrombosis risk scoring, and best practice recommendations on risk reduction strategies for at-risk individuals undergoing ovarian stimulation and embryo transfer cycles.
Article number: 5
Article Type: Analytical Review |
Subject:
Sterility
Received: 2026/07/11 | Accepted: 2026/07/28 | Published: 2026/07/30
Received: 2026/07/11 | Accepted: 2026/07/28 | Published: 2026/07/30
References
1. 1. Vander Borght M, Wyns C. Fertility and infertility: Definition and epidemiology. Clin Biochem. 2018;62:2-10. [DOI:10.1016/j.clinbiochem.2018.03.012] [PMID]
2. Sennström M, Rova K, Hellgren M, Hjertberg R, Nord E, Thurn L, et al. Thromboembolism and in vitro fertilization - a systematic review. Acta Obstet Gynecol Scand. 2017;96(9):1045-52. [DOI:10.1111/aogs.13147] [PMID]
3. Cox C, Roberts LN. Basics of diagnosis and treatment of venous thromboembolism. Journal of Thrombosis and Haemostasis. 2025;23(4):1185-202. [DOI:10.1016/j.jtha.2025.01.009] [PMID]
4. Shard A, Prodger C, Pavord S. Venous thromboembolism still leads on maternal death. Res Pract Thromb Haemost. 2025;9(1):102675. [DOI:10.1016/j.rpth.2024.102675] [PMID] [PMCID]
5. Grandone E, Colaizzo D, Vergura P, Cappucci F, Vecchione G, Lo Bue A, et al. Age and homocysteine plasma levels are risk factors for thrombotic complications after ovarian stimulation. Hum Reprod. 2004;19(8):1796-9. [DOI:10.1093/humrep/deh346] [PMID]
6. Jacobsen AF, Skjeldestad FE, Sandset PM. Ante- and postnatal risk factors of venous thrombosis: a hospital-based case-control study. J Thromb Haemost. 2008;6(6):905-12. [DOI:10.1111/j.1538-7836.2008.02961.x] [PMID]
7. Ata B, Urman B. Thrombophilia and assisted reproduction technology-any detrimental impact or unnecessary overuse? J Assist Reprod Genet. 2016;33(10):1305-10. [DOI:10.1007/s10815-016-0771-8] [PMID] [PMCID]
8. Goualou M, Noumegni S, de Moreuil C, Le Guillou M, De Coninck G, Hoffmann C, et al. Venous Thromboembolism Associated with Assisted Reproductive Technology: A Systematic Review and Meta-analysis. Thromb Haemost. 2023;123(3):283-94. [DOI:10.1055/s-0042-1760255] [PMID]
9. Filipovic-Pierucci A, Gabet A, Deneux-Tharaux C, Plu-Bureau G, Olié V. Arterial and venous complications after fertility treatment: A French nationwide cohort study. Eur J Obstet Gynecol Reprod Biol. 2019;237:57-63. [DOI:10.1016/j.ejogrb.2019.02.034] [PMID]
10. Balachandren N, Seshadri S, Yasmin E, Saab W, Gates C, Sayar Z, et al. Venous thromboembolism associated with medically assisted reproduction (MAR): British fertility society policy and practice guidance for assessment and prevention. Hum Fertil (Camb). 2024;27(1):2352387. [DOI:10.1080/14647273.2024.2352387] [PMID]
11. Farquhar C, Rombauts L, Kremer JA, Lethaby A, Ayeleke RO. Oral contraceptive pill, progestogen or oestrogen pretreatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques. Cochrane Database Syst Rev. 2017;5(5):Cd006109. [DOI:10.1002/14651858.CD006109.pub3] [PMID]
12. Dyer J, Wyke S, Lynch C. Hospital Episode Statistics data analysis of postoperative venous thromboembolus in patients undergoing urological surgery: a review of 126,891 cases. Ann R Coll Surg Engl. 2013;95(1):65-9. [DOI:10.1308/003588413X13511609956219] [PMID] [PMCID]
13. Ott J, Egarter C, Aguilera A. Dydrogesterone after 60 years: a glance at the safety profile. Gynecol Endocrinol. 2022;38(4):279-87. [DOI:10.1080/09513590.2021.2016692] [PMID]
14. Rova K, Passmark H, Lindqvist PG. Venous thromboembolism in relation to in vitro fertilization: an approach to determining the incidence and increase in risk in successful cycles. Fertil Steril. 2012;97(1):95-100. [DOI:10.1016/j.fertnstert.2011.10.038] [PMID]
15. Virkus RA, Løkkegaard E, Lidegaard Ø, Langhoff-Roos J, Nielsen AK, Rothman KJ, et al. Risk factors for venous thromboembolism in 1.3 million pregnancies: a nationwide prospective cohort. PLoS One. 2014;9(5):e96495. [DOI:10.1371/journal.pone.0096495] [PMID] [PMCID]
16. Sweetland S, Beral V, Balkwill A, Liu B, Benson VS, Canonico M, et al. Venous thromboembolism risk in relation to use of different types of postmenopausal hormone therapy in a large prospective study. J Thromb Haemost. 2012;10(11):2277-86. [DOI:10.1111/j.1538-7836.2012.04919.x] [PMID]
17. Zaat TR, Kostova EB, Korsen P, Showell MG, Mol F, van Wely M. Obstetric and neonatal outcomes after natural versus artificial cycle frozen embryo transfer and the role of luteal phase support: a systematic review and meta-analysis. Hum Reprod Update. 2023;29(5):634-54. [DOI:10.1093/humupd/dmad011] [PMID] [PMCID]
18. Hansen AT, Kesmodel US, Juul S, Hvas AM. Increased venous thrombosis incidence in pregnancies after in vitro fertilization. Hum Reprod. 2014;29(3):611-7. [DOI:10.1093/humrep/det458] [PMID]
19. Chan WS. The 'ART' of thrombosis: a review of arterial and venous thrombosis in assisted reproductive technology. Curr Opin Obstet Gynecol. 2009;21(3):207-18. [DOI:10.1097/GCO.0b013e328329c2b8] [PMID]
20. Wormer KC, Jangda AA, El Sayed FA, Stewart KI, Mumford SL, Segars JH. Is thromboprophylaxis cost effective in ovarian hyperstimulation syndrome: A systematic review and cost analysis. Eur J Obstet Gynecol Reprod Biol. 2018;224:117-24. [DOI:10.1016/j.ejogrb.2018.03.028] [PMID] [PMCID]
21. Olausson N, Mobarrez F, Zubarev R, Chernobrovkin A, Rutishauser D, Bremme K, et al. Changes in the plasma microvesicle proteome during the ovarian hyperstimulation phase of assisted reproductive technology. Sci Rep. 2020;10(1):13645. [DOI:10.1038/s41598-020-70541-w] [PMID] [PMCID]
22. Khorana AA, Dalal M, Lin J, Connolly GC. Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States. Cancer. 2013;119(3):648-55. [DOI:10.1002/cncr.27772] [PMID]
23. Barcroft J, Dayoub N, Thong KJ. Fifteen year follow-up of embryos cryopreserved in cancer patients for fertility preservation. J Assist Reprod Genet. 2013;30(11):1407-13. [DOI:10.1007/s10815-013-0024-z] [PMID] [PMCID]
24. Wun T, White RH. Epidemiology of cancer-related venous thromboembolism. Best Pract Res Clin Haematol. 2009;22(1):9-23. [DOI:10.1016/j.beha.2008.12.001] [PMID] [PMCID]
25. Pecker LH, Maher JY, Law JY, Beach MC, Lanzkron S, Christianson MS. Risks associated with fertility preservation for women with sickle cell anemia. Fertil Steril. 2018;110(4):720-31. [DOI:10.1016/j.fertnstert.2018.05.016] [PMID]
26. Lambalk CB, Banga FR, Huirne JA, Toftager M, Pinborg A, Homburg R, et al. GnRH antagonist versus long agonist protocols in IVF: a systematic review and meta-analysis accounting for patient type. Hum Reprod Update. 2017;23(5):560-79. [DOI:10.1093/humupd/dmx017] [PMID]
27. Nargund G, Fauser BC, Macklon NS, Ombelet W, Nygren K, Frydman R. The ISMAAR proposal on terminology for ovarian stimulation for IVF. Hum Reprod. 2007;22(11):2801-4. [DOI:10.1093/humrep/dem285] [PMID]
28. Zhang JJ, Merhi Z, Yang M, Bodri D, Chavez-Badiola A, Repping S, et al. Minimal stimulation IVF vs conventional IVF: a randomized controlled trial. Am J Obstet Gynecol. 2016;214(1):96.e1-8. [DOI:10.1016/j.ajog.2015.08.009] [PMID]
29. Nargund G, Waterstone J, Bland J, Philips Z, Parsons J, Campbell S. Cumulative conception and live birth rates in natural (unstimulated) IVF cycles. Hum Reprod. 2001;16(2):259-62. [DOI:10.1093/humrep/16.2.259] [PMID]
30. Rodgers RJ, Reid GD, Koch J, Deans R, Ledger WL, Friedlander M, et al. The safety and efficacy of controlled ovarian hyperstimulation for fertility preservation in women with early breast cancer: a systematic review. Hum Reprod. 2017;32(5):1033-45. [DOI:10.1093/humrep/dex027] [PMID]
31. Blondon M, Bodmer A, Thouvenin L, Lecompte T, Righini M, Fontana P, et al. Differential impact of tamoxifen and aromatase inhibitors on thrombin generation: the prospective HEMOBREAST cohort. Blood Adv. 2022;6(9):2884-92. [DOI:10.1182/bloodadvances.2021006623] [PMID] [PMCID]
32. Do not use your browser's 'BACK' button.
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
